Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations. Learn why I believe Novo Nordisk is ...

Novo Nordisk's once-daily oral Amycretin, a GLP-1/Amylin co-agonist, has shown promising results in early trials. With competitive weight loss percentages at various doses compared to other oral ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.